$LTBR
LIGHTBRIDGE Corp

2022 Q3 Form 10-Q Financial Statement

#000147793222005467 Filed on July 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.024M $1.440M $1.914M
YoY Change 14.8% -5.03% 7.5%
% of Gross Profit
Research & Development $172.9K $165.5K $262.8K
YoY Change -60.68% -39.46% -28.86%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.197M $1.605M $2.176M
YoY Change -0.27% -10.29% 1.12%
Operating Profit -$2.125M -$1.522M -$2.053M
YoY Change 11.06% -5.57% 0.2%
Interest Expense $87.94K $19.02K $3.510K
YoY Change 5573.55% -82.91% -91.23%
% of Operating Profit
Other Income/Expense, Net $71.34K $83.50K $123.4K
YoY Change -75.31% -53.03% 19.39%
Pretax Income -$2.038M -$1.503M -$2.050M
YoY Change 6.55% 1.87%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.038M -$1.503M -$2.050M
YoY Change 6.55% -6.67% 1.87%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$0.14 -$0.20
Diluted Earnings Per Share -$183.8K -$0.14 -$0.20
COMMON SHARES
Basic Shares Outstanding 11.08M shares 10.52M shares 10.28M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.28M $29.27M $28.23M
YoY Change 93.91% 111.23% 85.22%
Cash & Equivalents $31.28M $29.27M $28.23M
Short-Term Investments
Other Short-Term Assets $305.9K $409.3K $558.8K
YoY Change 23.75% 5.1% -12.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $31.59M $29.68M $28.79M
YoY Change 91.56% 97.45% 81.38%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $100.0K $100.0K $100.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $107.8K $107.8K $101.6K
YoY Change 6.08% 7.52% 12.87%
TOTAL ASSETS
Total Short-Term Assets $31.59M $29.68M $28.79M
Total Long-Term Assets $107.8K $107.8K $101.6K
Total Assets $31.70M $29.79M $28.89M
YoY Change 91.04% 96.85% 81.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.0K $100.0K $100.0K
YoY Change 51.52% 53.85% -44.44%
Accrued Expenses $1.100M $400.0K $100.0K
YoY Change 18.53% -60.82% -77.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.190M $482.7K $452.8K
YoY Change 7.45% -60.25% -28.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.190M $482.7K $452.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.190M $482.7K $452.8K
YoY Change 7.45% -60.25% -28.12%
SHAREHOLDERS EQUITY
Retained Earnings -$142.6M -$140.5M
YoY Change 5.86% 5.85%
Common Stock $11.54K $11.01K
YoY Change 60.08% 66.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.51M $29.30M $28.43M
YoY Change
Total Liabilities & Shareholders Equity $31.70M $29.79M $28.89M
YoY Change 91.04% 96.85% 81.0%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.038M -$1.503M -$2.050M
YoY Change 6.55% -6.67% 1.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.036M -$1.135M -$1.934M
YoY Change -8.51% -16.64% -69.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$6.170K
YoY Change -100.0% -57.91%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$6.170K $0.00
YoY Change -100.0% -57.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.413M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.052M 2.182M $5.413M
YoY Change -10.52%
NET CHANGE
Cash From Operating Activities -1.036M -1.135M -$1.934M
Cash From Investing Activities 0.000 -6.170K $0.00
Cash From Financing Activities 3.052M 2.182M $5.413M
Net Change In Cash 2.016M 1.041M $3.479M
YoY Change -11.47% -175.69% -155.27%
FREE CASH FLOW
Cash From Operating Activities -$1.036M -$1.135M -$1.934M
Capital Expenditures $0.00 -$6.170K
Free Cash Flow -$1.036M -$1.128M
YoY Change -8.4% -16.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001084554
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
22522 usd
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13500000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9759223 shares
CY2021Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
100000.0 usd
ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
200000.0 usd
us-gaap Profit Loss
ProfitLoss
-3600000.0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34487
dei Entity Registrant Name
EntityRegistrantName
LIGHTBRIDGE CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1975651
dei Entity Address Address Line1
EntityAddressAddressLine1
11710 Plaza America Drive,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2000
dei Entity Address City Or Town
EntityAddressCityOrTown
Reston
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20190
dei City Area Code
CityAreaCode
571
dei Local Phone Number
LocalPhoneNumber
730-1200
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
LTBR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11082218 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11009000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9759223 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
11009 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
CY2021Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1439684 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1515899 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3353249 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
165476 usd
us-gaap Operating Expenses
OperatingExpenses
3781547 usd
us-gaap Operating Expenses
OperatingExpenses
3941523 usd
CY2022Q2 ltbr Distribution From Joint Venture
DistributionFromJointVenture
0 usd
CY2021Q2 ltbr Distribution From Joint Venture
DistributionFromJointVenture
110000 usd
ltbr Distribution From Joint Venture
DistributionFromJointVenture
0 usd
ltbr Distribution From Joint Venture
DistributionFromJointVenture
110000 usd
CY2021Q2 ltbr Contributed Services Research And Development
ContributedServicesResearchAndDevelopment
67794 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
83501 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
177794 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
206854 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1521659 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1611419 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
19017 usd
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1322 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4631 usd
CY2022Q2 ltbr Foreign Currency Transaction Gain
ForeignCurrencyTransactionGain
0 usd
CY2021Q2 ltbr Foreign Currency Transaction Gain
ForeignCurrencyTransactionGain
0 usd
ltbr Foreign Currency Transaction Gain
ForeignCurrencyTransactionGain
0 usd
ltbr Foreign Currency Transaction Gain
ForeignCurrencyTransactionGain
33694 usd
CY2022Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
19017 usd
CY2021Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1322 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
22522 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
38325 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1502642 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1610097 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3552171 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3622085 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-3552171 usd
us-gaap Net Income Loss
NetIncomeLoss
-3622085 usd
CY2022Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 usd
CY2021Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-133313 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-264747 usd
CY2022Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 usd
CY2021Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
58408 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
115897 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1502642 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1801818 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3552171 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4002729 usd
CY2022Q2 ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.14
CY2021Q2 ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.27
ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.34
ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.61
CY2022Q2 ltbr Weighted Average Numberof Common Share Outstanding Basic And Diluted
WeightedAverageNumberofCommonShareOutstandingBasicAndDiluted
10523238 shares
CY2021Q2 ltbr Weighted Average Numberof Common Share Outstanding Basic And Diluted
WeightedAverageNumberofCommonShareOutstandingBasicAndDiluted
6595483 shares
ltbr Weighted Average Numberof Common Share Outstanding Basic And Diluted
WeightedAverageNumberofCommonShareOutstandingBasicAndDiluted
10403922 shares
ltbr Weighted Average Numberof Common Share Outstanding Basic And Diluted
WeightedAverageNumberofCommonShareOutstandingBasicAndDiluted
6592454 shares
us-gaap Net Income Loss
NetIncomeLoss
-3552171 usd
us-gaap Net Income Loss
NetIncomeLoss
-3622085 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
15000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
30000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
246403 usd
us-gaap Payments To Acquire Other Receivables
PaymentsToAcquireOtherReceivables
0 usd
us-gaap Payments To Acquire Other Receivables
PaymentsToAcquireOtherReceivables
785000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
217001 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
211655 usd
ltbr Increase Decrease In Accrued Legal Settlement Costs
IncreaseDecreaseInAccruedLegalSettlementCosts
-3525000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7661028 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14655 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14655 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7675683 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24747613 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21531665 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29268074 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13855982 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
ltbr Accumulated Preferred Stock Dividend
AccumulatedPreferredStockDividend
0 usd
ltbr Accumulated Preferred Stock Dividend
AccumulatedPreferredStockDividend
380644 usd
ltbr Conversion Of Series A Convertible Preferred Stock To Common Stock And Payment Of Paid In Kind Dividends To Series A Preferred Stockholder
ConversionOfSeriesAConvertiblePreferredStockToCommonStockAndPaymentOfPaidInKindDividendsToSeriesAPreferredStockholder
0 usd
ltbr Conversion Of Series A Convertible Preferred Stock To Common Stock And Payment Of Paid In Kind Dividends To Series A Preferred Stockholder
ConversionOfSeriesAConvertiblePreferredStockToCommonStockAndPaymentOfPaidInKindDividendsToSeriesAPreferredStockholder
17173 usd
ltbr Payment Of Accrued Liabilities With Common Stock
PaymentOfAccruedLiabilitiesWithCommonStock
54690 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
24791127 usd
CY2022Q1 ltbr Shares Issued Registered Offerings Net Of Offering Costs Amount
SharesIssuedRegisteredOfferingsNetOfOfferingCostsAmount
5412863 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
15000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
264936 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2049529 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
28434397 usd
CY2022Q2 ltbr Shares Issued Registered Offerings Net Of Offering Costs Amount
SharesIssuedRegisteredOfferingsNetOfOfferingCostsAmount
2181982 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
15000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
173772 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17207557 usd
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
69690 usd
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
60068 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2011988 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15325327 usd
CY2021Q2 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
15000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
186335 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1610097 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
13916565 usd
CY2022Q2 us-gaap Cash
Cash
29300000 usd
CY2022Q2 ltbr Working Capital Surplus
WorkingCapitalSurplus
29200000 usd
ltbr Net Cash Used In Operating Activities
NetCashUsedInOperatingActivities
3100000 usd
us-gaap Profit Loss
ProfitLoss
-3600000 usd
CY2022Q2 ltbr Accumulated Deficit
AccumulatedDeficit
-140500000 usd
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
75000000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company will need additional funding by way of a combination of strategic alliances, government grants, further offerings of equity securities, or an offering of debt securities in order to support its future R&amp;D activities required to further enhance and complete the development of its fuel products to a proof-of-concept stage and a commercial stage thereafter.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurance that the Company will be able to successfully continue to conduct its operations if there is a lack of financial resources available in the future to continue its fuel development activities, and a failure to do so would have a material adverse effect on the Company’s future R&amp;D activities, financial position, results of operations, and cash flows. Also, the success of the Company’s operations will be subject to other numerous contingencies, some of which are beyond management’s control. These contingencies include general and regional economic conditions, contingent liabilities, potential competition with other nuclear fuel developers, including those entities developing accident tolerant fuels, changes in government regulations, support for nuclear power, changes in accounting and taxation standards, inability to achieve overall short-term and long-term R&amp;D milestones toward commercialization, future impairment charges to its assets, and global or regional catastrophic events. The Company may also be subject to various additional political, economic, and other uncertainties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risk to the international community as the virus spread globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak a pandemic, based on increased exposure globally. The current spread of COVID-19, including the emergence and spread of variant strains of the virus, that is impacting global economic activity and market conditions could lead to adverse changes in the Company’s ability to conduct R&amp;D activities with the United States national labs and others. The COVID-19 outbreak impacted our business operations and results of operations for the years ended December 31, 2021 and 2020, which resulted in a delay of our R&amp;D work and reduction of R&amp;D expenses and an increase in general and administrative expenses due to severance payments to former employees. However, the effects of the pandemic are fluid and changing rapidly, including with respect to vaccine and treatment developments and deployment and potential mutations of COVID-19. While the Company continues to monitor the impact of COVID-19 on its business, the Company is unable to accurately predict the ultimate impact on future results of operations, financial condition and liquidity that COVID-19 will have due to various uncertainties, including the geographic spread of the virus, the severity of the disease, the duration of the outbreak, and actions that may be taken by governmental authorities and other third parties. </p>
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Interest Income Securities Us Treasury
InterestIncomeSecuritiesUSTreasury
14000000.0 usd
us-gaap Interest Income Securities Us Treasury
InterestIncomeSecuritiesUSTreasury
9000000.0 usd
CY2022Q2 us-gaap Deposits
Deposits
15300000 usd
CY2021Q4 us-gaap Deposits
Deposits
15700000 usd
ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
100000 usd
CY2021Q2 ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
200000 usd
CY2022Q2 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
100000 usd
ltbr Leases
Leases
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASU 2016-02, <em>Leases (Topic 842)</em>, which requires recognition of most lease arrangements on the balance sheet, the Company recognizes operating lease right of use assets and liabilities at commencement date based on the present value of the future minimum lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet in accordance with the short-term lease recognition exemption. The Company applies the practical expedient to not separate lease and non-lease components for all leases that qualify. Lease expense is recognized on a straight-line basis over the lease term. The Company has only one lease for office rent and the lease is for a term of 12 months without renewal options. See Note 4 for additional information. </p>
ltbr Common Stock Warrantstspolicytextblock
CommonStockWarrantstspolicytextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Common stock warrants are accounted for as a derivative in accordance with ASC 815, <em>Derivatives and Hedging,</em> if the stock warrants contain terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as a derivative. Warrant instruments that could potentially require “net cash settlement” in the absence of explicit language precluding such settlement are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All outstanding warrants expired on May 16, 2022.</p>
CY2022Q2 ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-1500000 usd
CY2021Q2 ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-1800000 usd
ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-3600000 usd
ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-4000000.0 usd
CY2022Q2 ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
10523238 shares
CY2021Q2 ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
6595483 shares
ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
10403922 shares
ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
6592454 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1500000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1800000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3600000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4000000.0 usd
CY2022Q2 us-gaap Dilutive Securities
DilutiveSecurities
0 usd
CY2021Q2 us-gaap Dilutive Securities
DilutiveSecurities
0 usd
us-gaap Dilutive Securities
DilutiveSecurities
0 usd
us-gaap Dilutive Securities
DilutiveSecurities
0 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-1500000 usd
CY2021Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-1800000 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-3600000 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-4000000.0 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10523238 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6595483 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10403922 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6592454 shares
CY2022Q2 ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
10523238 shares
CY2021Q2 ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
6595483 shares
ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
10403922 shares
ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
6592454 shares
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q2 ltbr Warrants Outstanding
WarrantsOutstanding
0 shares
ltbr Warrants Outstanding
WarrantsOutstanding
45577 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
520565 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
563734 shares
CY2022Q2 ltbr Rsas Outstanding
RsasOutstanding
188588 shares
ltbr Rsas Outstanding
RsasOutstanding
0 shares
CY2022Q2 ltbr Rsus Outstanding
RsusOutstanding
0 shares
ltbr Rsus Outstanding
RsusOutstanding
243800 shares
CY2022Q2 ltbr Series A Convertible Preferred Stock To Common Shares
SeriesAConvertiblePreferredStockToCommonShares
0 shares
ltbr Series A Convertible Preferred Stock To Common Shares
SeriesAConvertiblePreferredStockToCommonShares
80235 shares
CY2022Q2 ltbr Series B Convertible Preferred Stock To Common Shares
SeriesBConvertiblePreferredStockToCommonShares
0 shares
ltbr Series B Convertible Preferred Stock To Common Shares
SeriesBConvertiblePreferredStockToCommonShares
281690 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
709153 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1215036 shares
CY2021Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
100000 usd
CY2022Q2 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
100000 usd
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
0 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
100000 usd
CY2022Q2 ltbr Accrued Bonuses
AccruedBonuses
400000 usd
CY2021Q4 ltbr Accrued Bonuses
AccruedBonuses
0 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
500000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
200000 usd
ltbr Operating Lease Term
OperatingLeaseTerm
P12Y
ltbr Operating Lease Monthly Payment
OperatingLeaseMonthlyPayment
8000 usd
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
4700000000 usd
CY2022Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
23000 usd
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
47000 usd
CY2021Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
31000 usd
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
62000 usd
CY2021Q4 ltbr Total Project Value
TotalProjectValue
500000 usd
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
100000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
200000 usd
CY2021Q3 ltbr Total Project Value
TotalProjectValue
700000 usd
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
100000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
200000 usd
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11009000 shares
CY2022Q2 ltbr Stock Options Outstanding
StockOptionsOutstanding
11718153 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
188588 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9759223 shares
CY2022Q2 ltbr Convertible Restricted Stock
ConvertibleRestrictedStock
188588 shares
CY2021Q4 ltbr Convertible Restricted Stock
ConvertibleRestrictedStock
188588 shares
CY2021Q4 ltbr Stock Options Outstanding
StockOptionsOutstanding
10532101 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
45577 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1537 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0102 pure
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
0 usd
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P2Y
CY2022Q2 us-gaap Share Price
SharePrice
6.27
ltbr Share Based Compensation Share Based Payment Award Options Outstanding Number
ShareBasedCompensationShareBasedPaymentAwardOptionsOutstandingNumber
538713 shares
ltbr Weighted Average Exercise Price Beginning
WeightedAverageExercisePriceBeginning
18.51
ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOptionsNonvestedWeightedAverageGrantDateFairValue
12.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
13514 shares
ltbr Weighted Average Exercise Price Stock Options Granted
WeightedAverageExercisePriceStockOptionsGranted
6.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.70
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
ltbr Weighted Average Exercise Price Stock Options Exercised
WeightedAverageExercisePriceStockOptionsExercised
0
ltbr Weighted Average Fair Value Stock Options Exercised
WeightedAverageFairValueStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
31662 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.29
ltbr Weighted Average Fair Value Stock Options Expired
WeightedAverageFairValueStockOptionsExpired
2.37
ltbr Share Based Compensation By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationByShareBasedPaymentAwardOptionsOutstandingNumber
520565 shares
ltbr Weighted Average Exercise Price End
WeightedAverageExercisePriceEnd
18.87
ltbr Share Based Compensatio By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensatioByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.32
ltbr Options Outstanding Options Exercisable
OptionsOutstandingOptionsExercisable
508799 shares
ltbr Weighted Average Exercise Price Options Exercisable
WeightedAverageExercisePriceOptionsExercisable
19.17
ltbr Weighted Average Fair Value Options Exercisable
WeightedAverageFairValueOptionsExercisable
13.53
ltbr Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm
P4Y11M19D
CY2022Q2 ltbr Number Of Awards Stock Option Outstanding A
NumberOfAwardsStockOptionOutstandingA
520565 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
18.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y10M17D
CY2022Q2 ltbr Number Of Awards Stock Options Vested
NumberOfAwardsStockOptionsVested
508799 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.17
CY2022Q2 ltbr Restricted Stock Award Not Included Outstanding Shares
RestrictedStockAwardNotIncludedOutstandingShares
188588 shares
CY2021Q4 ltbr Restricted Stock Award Not Included Outstanding Shares
RestrictedStockAwardNotIncludedOutstandingShares
188588 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
188588 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2022Q2 ltbr Share Based Compensation Arrangement By Rs As Options Outstanding Number
ShareBasedCompensationArrangementByRSAsOptionsOutstandingNumber
377176 shares
CY2022Q2 ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue
10.69
CY2021Q4 ltbr Share Based Compensation Arrangement By Rs As Options Outstanding Number
ShareBasedCompensationArrangementByRSAsOptionsOutstandingNumber
377176 shares
CY2021Q4 ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue
10.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0 shares
ltbr Schedule Of Fair Value Of Options
ScheduleOfFairValueOfOptions
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ending December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Scheduled vesting</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">62,862</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">62,864</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">62,862</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">188,588</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13500000 shares
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
169834944 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140543444 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
29302509 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29785170 usd
CY2022Q2 ltbr Contributed Services Research And Development
ContributedServicesResearchAndDevelopment
83501 usd

Files In Submission

Name View Source Status
0001477932-22-005467-index-headers.html Edgar Link pending
0001477932-22-005467-index.html Edgar Link pending
0001477932-22-005467.txt Edgar Link pending
0001477932-22-005467-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ltbr-20220630.xsd Edgar Link pending
ltbr-20220630_cal.xml Edgar Link unprocessable
ltbr-20220630_def.xml Edgar Link unprocessable
ltbr-20220630_lab.xml Edgar Link unprocessable
ltbr-20220630_pre.xml Edgar Link unprocessable
ltbr_10q.htm Edgar Link pending
ltbr_10q_htm.xml Edgar Link completed
ltbr_ex311.htm Edgar Link pending
ltbr_ex312.htm Edgar Link pending
ltbr_ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending